← boardnext 2026-11next 2027-07next 2028-01-31
ANL
Adlai Nortye Biopharma Co., Ltd.distress 5/10 · elevated risk$13.03-2%today-22% from 52w high
Oncology 3
Lead: Solid Tumors (Phase 1) · target PD-L1
Revenue
pre-revenue
Liquidity
$12M
Runway
0.4 yrs
Shares 1y
—
Price & events
+538.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+14.8%
1W
+22.9%
1M
-12.6%
3M
+395.4%
6M
+786.4%
1Y
+269.1%
2Y
—
5Y
-13.1%
All
Overview
- Volume
- 1.89K
- 52 Week Range
- $0.88 – $16.60
- Float Shares
- 18.42M
- Short %
- 5.73%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 24.55%
- RVOL
- 0.01x
- Beta
- 1.11
Pipeline stages · 6 programs
AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AN8025 is a multifunctional antibody fusion protein
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AN9025 oral capsule
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Buparlisib & Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AN0025
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AN2025, AN0025, Atezolizumab 1200 mg in 20 ML InjectionPD-L1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-01 | Phase 1 | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2 | Advanced Solid Tumor, Advanced Lymphoma | — | recruiting |
| 2027-07 Estimated 50% readout ~2027-07-31 | Phase 1 | AN8025 is a multifunctional antibody fusion protein | Advanced Solid Tumor (Phase 1) | — | recruiting |
| 2028-01-31 Estimated 50% readout ~2028-03-01 | Phase 1 | AN9025 oral capsule | Solid Tumors (Phase 1), RAS Mutation | — | recruiting |
| 2025-12 | Phase 1 | AN0025 | Esophageal Cancer | 32 | suspended |
| 2025-11-02 | Phase 3 | Buparlisib & Paclitaxel | Head and Neck Cancer | 487 | completed |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-01-24 | Phase 1 | AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection | Locally Advanced Solid Tumor | 47 | completed |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $29 (+119% upside) · 5 analysts
- 2026-06-22Cantor FitzgeraldOverweight
- 2026-05-28OppenheimerOutperform
- 2026-05-14Jones TradingBuy
- 2026-04-20HC Wainwright & Co.Buy
- 2026-02-13HC Wainwright & Co.Neutral → Buy
- 2025-06-02HC Wainwright & Co.Buy → Neutral
Competitors — PD-L1
Recent news
- 2026-07-21Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
- 2026-07-20Adlai Nortye (Nasdaq: ANL) revises selling shareholders for 98.6M registered shares - Stock Titan
- 2026-07-17Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
- 2026-07-17Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
- 2026-07-17Adlai Nortye (NASDAQ: ANL) doses first patient in weekly AN9025 trial arm - Stock Titan
- 2026-07-16Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
- 2026-07-16Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
- 2026-07-16Adlai Nortye Starts Weekly Dosing Test for RAS-Mutated Solid Tumors - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.